About Red Cell Therapeutics™

At Rubius Therapeutics, we are creating red blood cells and turning them into potential medicines, called Red Cell Therapeutics™.

We make these Red Cell Therapeutics, or RCTs, by genetically engineering cells to produce therapeutic proteins to help people with cancer and autoimmune diseases.

Immune System Activation for the Treatment of Cancer

RCTs are designed to have combinations of cancer-fighting proteins on the cell surface that activate and amplify the body’s own immune system to attack cancer cells.

Retraining the Immune System to Treat Autoimmune Diseases

By exposing the immune system to small amounts of the disease-causing antigen that creates the autoimmune disorder, RCTs are designed to retrain a patient’s immune system so it recognizes the body as “self” instead of something foreign to be attacked. This process is also known as tolerance induction.

Sign up to learn more about Red Cell Therapeutics™

and receive updates about clinical trials that might be available in your area for the potential treatment of cancer and autoimmune diseases for yourself or a loved one.

Please correct the following errors and submit the form again.

Please enter your first name.

Please enter your last name.

Please enter a valid email address.

Please enter your 10-digit phone number.

Please enter your 5-digit zip code.

Disease

Please select at least one disease.

I AGREE TO ALLOW RUBIUS TO STORE AND PROCESS MY PERSONAL DATA SO THAT I MAY RECEIVE COMMUNICATIONS FROM RUBIUS. In order to provide you the content requested, we need to store and process the personal data you provided above. You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy. You can unsubscribe from these communications by following the ‘unsubscribe’ link in any email we send, or email us at clinicialtrials@rubiustx.com and ask us to remove you from our communications.

Thank you

We will contact you about your submission